Antibody Drug Conjugates Global Market To Reach Value Of About $6 Billion In 2025

29 Nov, 2021

Check out TBRC’s sale today for

The antibody-drug conjugates (ADCs) market consists of sales of antibody-drug conjugates. ADCs are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers.

Global Antibody Drug Conjugates Market Size And Drivers:

The global antibody drug conjugates market is expected to grow from $2.34 billion in 2020 to $2.6 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The antibody-drug conjugates (ADCs) market is expected to reach $6.12 billion in 2025 at a CAGR of 23.9%. The antibody drug conjugates market is being driven by rising incidences of cancer globally.

Request For A Sample For The Global Antibody Drug Conjugates Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2569&type=smp

Trends In The Global Antibody Drug Conjugates Market

Manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For instance, in March 2019, Astrazeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company for the proprietary antibody drug conjugate trastuzumab deruxtecan (DS-8201). In April 2019, Shanghai Miracogen entered into an agreement with Netherlands based Synaffix to use its tools for building antibody drug conjugates. According to the deal, Miracogen is licensing two platforms from Synaffix which is expected to boost its product pipeline.

Global Antibody Drug Conjugates Market Segments:
The global antibody drug conjugates market is further segmented –
By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Others
By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others
By Product: Adcertis, Kadcyla, Others
By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others
By End User: Hospital, Clinics, Others
By Geography: The global antibody drug conjugates market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Antibody Drug Conjugates Market At:

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Antibody Drug Conjugates Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides antibody drug conjugates market overviews, analyzes and forecasts market size and growth for the global antibody drug conjugates market, antibody drug conjugates market share, antibody drug conjugates market players, antibody drug conjugates market segments and geographies, antibody drug conjugates market’s leading competitors’ revenues, profiles and market shares. The antibody drug conjugates market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.